Shu Jiang

Shu Jiang (also known as Joy Jiang), Ph.D. is a Canadian biostatistician and associate professor of surgery in the [https://publichealthsciences.wustl.edu/ Division of Public Health Sciences] at WashU School of Medicine in St. Louis. She is also Co-Founder, with Graham Colditz, of Prognosia Inc, a technology company that develops AI models that assess digital mammograms to accurately predict the risk of breast cancer. Prognosia’s first tool, Prognosia Breast, earned Breakthrough Device Designation from the U.S. Food and Drug Administration in June, 2025, and the company was acquired by Lunit in September 2025.

Jiang is known for her contributions to breast cancer risk prediction using high-dimensional mammogram images. In April 2023, The New York Times and CNN interviewed Jiang for a feature about breast density and cancer risk, in which she discussed recent findings on how changes in density over time may indicate elevated breast cancer risk. In December 2024, [https://www.usnews.com/ U.S. News & World Report] cited Jiang in an article about artificial intelligence and breast cancer screening. Discussing her team’s work on longitudinal mammogram analysis, Jiang said: “Our new method is able to detect subtle changes over time in repeated mammogram images that are not visible to the eye.” More recently, media coverage has also included [https://www.breastcancer.org BreastCancer.org], which described a newer AI-based approach in which Jiang used multiple years of mammograms to enhance risk prediction.

She is an associate editor for the journal Biometrics and a statistical reviewer for JAMA Network Open. Among other awards and honors, Jiang has been named a Forbes 30 Under 30 in Healthcare in 2023 and received the MERIT award from the National Cancer Institute (2021-2027). Provided by Wikipedia